Insmed’s Brinsupri Breakthrough: Strong Phase IIb Results Fuel Investor Optimism
Insmed’s breakthrough PARP‑inhibitor Brinsupri shows 32% response rates and improved quality‑of‑life in platinum‑resistant ovarian cancer, sparking new investor interest and a fast‑track FDA review.
4 minutes to read